CHEBI:47781 - desipramine

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name desipramine
ChEBI ID CHEBI:47781
Definition A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Stars This entity has been manually annotated by the ChEBI Team.
Secondary ChEBI IDs CHEBI:47393, CHEBI:4448
Supplier Information
Download Molfile XML SDF
more structures >>
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C18H22N2
Net Charge 0
Average Mass 266.38076
Monoisotopic Mass 266.178
InChI InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
InChIKey HCYAFALTSJYZDH-UHFFFAOYSA-N
SMILES CNCCCN1c2ccccc2CCc2ccccc12
Roles Classification
Biological Role(s): adrenergic uptake inhibitor
Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
serotonin uptake inhibitor
A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
cholinergic antagonist
Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
H1-receptor antagonist
H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
drug allergen
Any drug which causes the onset of an allergic reaction.
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
An EC 3.1.4.* (phosphoric diester hydrolase) inhibitor that interferes with the action of sphingomyelin phosphodiesterase (EC 3.1.4.12).
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
Application(s): adrenergic uptake inhibitor
Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
serotonin uptake inhibitor
A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
cholinergic antagonist
Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
H1-receptor antagonist
H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
antidepressant
Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
drug allergen
Any drug which causes the onset of an allergic reaction.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing desipramine (CHEBI:47781) has role α-adrenergic antagonist (CHEBI:37890)
desipramine (CHEBI:47781) has role adrenergic uptake inhibitor (CHEBI:35640)
desipramine (CHEBI:47781) has role antidepressant (CHEBI:35469)
desipramine (CHEBI:47781) has role cholinergic antagonist (CHEBI:48873)
desipramine (CHEBI:47781) has role drug allergen (CHEBI:88188)
desipramine (CHEBI:47781) has role EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor (CHEBI:76811)
desipramine (CHEBI:47781) has role EC 3.4.21.26 (prolyl oligopeptidase) inhibitor (CHEBI:76779)
desipramine (CHEBI:47781) has role H1-receptor antagonist (CHEBI:37955)
desipramine (CHEBI:47781) has role serotonin uptake inhibitor (CHEBI:50949)
desipramine (CHEBI:47781) is a dibenzoazepine (CHEBI:47804)
desipramine (CHEBI:47781) is a secondary amino compound (CHEBI:50995)
Incoming desipramine hydrochloride (CHEBI:4449) has part desipramine (CHEBI:47781)
IUPAC Name
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine
INNs Sources
desipramina ChEBI
désipramine ChEBI
desipramine ChEBI
desipraminum ChEBI
Synonyms Sources
3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE PDBeChem
5-(γ-methylaminopropyl)iminodibenzyl ChemIDplus
demethylimipramine ChemIDplus
Desipramin ChemIDplus
Desipramine KEGG COMPOUND
desmethylimipramine NIST Chemistry WebBook
DMI ChemIDplus
monodemethylimipramine ChemIDplus
N-(3-methylaminopropyl)iminobibenzyl ChemIDplus
norimipramine NIST Chemistry WebBook
Database Links Databases
812 DrugCentral
C06943 KEGG COMPOUND
D07791 KEGG DRUG
DB01151 DrugBank
Desipramine Wikipedia
DSM PDBeChem
HMDB0015282 HMDB
LSM-3351 LINCS
View more database links
Registry Numbers Types Sources
1432747 Reaxys Registry Number Reaxys
1432747 Beilstein Registry Number ChemIDplus
50-47-5 CAS Registry Number KEGG COMPOUND
50-47-5 CAS Registry Number ChemIDplus
50-47-5 CAS Registry Number NIST Chemistry WebBook
Citations Waiting for Citations Types Sources
11041270 PubMed citation Europe PMC
11287497 PubMed citation Europe PMC
19328214 PubMed citation Europe PMC
20825390 PubMed citation Europe PMC
24399719 PubMed citation Europe PMC
Last Modified
22 February 2017